KPTI Stock News 26.34 05/13/2014 19:31:27 Karyopharm Therapeutics

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Karyopharm Therapeutics Inc (KPTI) 26.34 $KPTI

Karyopharm Therapeutics Reports First Quarter Financial Results for 2014
GlobeNewswire - Wed May 07, 3:53PM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today reported financial results for the fiscal quarter ended March 31, 2014, and also provided highlights of its clinical development activity.

Karyopharm to Present at Upcoming Healthcare Conferences
GlobeNewswire - Mon May 05, 4:43PM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced that the company is scheduled to make the following presentations:

Phase 2 Study of Selinexor (KPT-330) Initiated by Karyopharm in Patients With Recurrent Glioblastoma After Failure of Radiation and Temozolomide (KING Study)
GlobeNewswire - Tue Apr 29, 3:46PM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the initiation of a Phase 2 trial of its novel, oral Selective Inhibitor of Nuclear Export (SINE) compound Selinexor (KPT-330) in patients with glioblastoma following treatment with radiation and temozolomide. The study, referred to as the KING study, is being run by Drs. Morten Mau-Sørensen at the Rigshospitalet in Copenhagen, Denmark, Andrew Lassman at Columbia University, New York, and Patrick Wen, Dana Farber Cancer Institute, Boston, Massachusetts.

Karyopharm Therapeutics reports launch of Phase 2 Study of Selinexor in patients with advanced gynecologic malignancies
M2 - Fri Apr 25, 4:37AM CDT
Pharmaceutical company Karyopharm Therapeutics (NasdaqGS:KPTI) disclosed on Thursday the start of a Phase 2 trial of its SINE) compound Selinexor (KPT-330) in patients with advanced gynecologic malignancies including cervical, ovarian and uterine carcinomas.

Phase 2 Study of Selinexor (KPT-330) Initiated by Karyopharm in Patients With Advanced Gynecologic Malignancies (SIGN Study)
GlobeNewswire - Thu Apr 24, 6:02AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the initiation of a Phase 2 trial of its novel, oral Selective Inhibitor of Nuclear Export (SINE) compound Selinexor (KPT-330) in patients with advanced gynecologic malignancies including cervical, ovarian and uterine carcinomas. The study, referred to as the SIGN Study, is being led by Ignace Vergote, MD, at the University Hospitals, Leuven, Belgium. SIGN is also open at Rigshospitalet in Copenhagen, Aalborg University Hospital, Aalborg, and Herlev Hospital, Herlev, all in Denmark.

Karyopharm Starts Phase I Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 4:10PM CDT
Karyopharm Therapeutics starts a phase I study which will evaluate selinexor in pediatric patients with relapsed or refractory ALL or AML

Karyopharm Announces Five Clinical Data Presentations at ASCO 2014
GlobeNewswire - Tue Apr 22, 6:05AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced that clinical and preclinical data for its lead drug candidate, Selinexor (KPT-330), a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, will be presented at the 50 Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held from May 30 to June 3, 2014 in Chicago, Illinois. Clinical results to be presented include updated data from Karyopharm's Phase 1 studies in patients with advanced hematologic malignancies, solid tumors and sarcomas. Karyopharm will host an investor and analyst briefing Monday, June 2, 2014 in Chicago, Illinois at 6:30 p.m. CT.

Karyopharm Announces a Phase 1 Trial of Selinexor (KPT-330) in Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)
GlobeNewswire - Mon Apr 21, 6:05AM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the initiation of its first pediatric clinical study, a Phase 1 trial of its novel, oral Selective Inhibitor of Nuclear Export (SINE) compound Selinexor (KPT-330) in pediatric patients. The trial will enroll up to 28 children with relapsed or refractory acute lymphoblastic leukemia (ALL) or acute myeloblastic leukemia (AML). The study is being led by Dana-Farber/Boston Children's Cancer and Blood Disorders Center under the direction of principal investigator Andrew Place, MD, PhD, Associate Director of Developmental Therapeutics, and has been partially funded by a grant from the William Lawrence & Blanche Hughes Foundation (clinicaltrials.gov: NCT02091245).

Karyopharm Announces Initiation of a Phase 1 Study of Decitabine (Dacogen(R)) and Selinexor (KPT-330) in Acute Myeloid Leukemia (AML)
GlobeNewswire - Tue Apr 15, 3:15PM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the initiation of a Phase 1 combination trial of its novel, oral Selective Inhibitor of Nuclear Export (SINE) compound Selinexor (KPT-330) in combination with the DNA methylation inhibitor decitabine (Dacogen) in patients with relapsed or refractory acute myeloid leukemia (AML) and in patients age greater-than or equal to60 years with newly diagnosed AML. The study is being conducted at The Ohio State University Comprehensive Cancer Center under the direction of principal investigator Ramiro Garzon, MD, Associate Professor.

Karyopharm elects Chris Primiano as VP
M2 - Fri Apr 11, 7:31AM CDT
US-based pharmaceutical company Karyopharm Therapeutics (NasdaqGS:KPTI) announced on Thursday that it has hired Christopher B. Primiano as its vice president, general counsel and secretary.

Karyopharm Appoints Chris Primiano as General Counsel
GlobeNewswire - Thu Apr 10, 3:35PM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the appointment of Christopher B. Primiano as Vice President, General Counsel and Secretary.

Karyopharm Therapeutics signs preferred provider agreement with Clinipace Worldwide
M2 - Thu Apr 10, 5:19AM CDT
Pharmaceutical company Karyopharm Therapeutics (NasdaqGS:KPTI) revealed on Wednesday the execution of a preferred provider agreement to manage several clinical programmes, including oncology, wound healing and other diseases in partnership with Clinipace Worldwide .

Karyopharm Therapeutics Inc. Enters into Preferred Provider Agreement with Clinipace Worldwide
Business Wire - Wed Apr 09, 9:00AM CDT
Clinipace Worldwide, a global digital clinical research organization (dCRO), announced today that Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, has entered into a preferred provider agreement with Clinipace to manage several clinical programs, including oncology, wound healing, and other diseases.

Karyopharm Therapeutics to Present at 13th Annual Needham Healthcare Conference
GlobeNewswire - Tue Apr 08, 12:26PM CDT
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, announced today that Michael Kauffman, Chief Executive Officer, is scheduled to present a company overview at the 13 Annual Needham Healthcare Conference. The conference is being held at The Westin Grand Central Hotel in New York City. The presentation is scheduled for Wednesday, April 9, 2014 at 8:00 am EDT.

Appointments, Financial Reports, and FDA Approvals - Analyst Notes on Hospira, Karyopharm, Revance, Pluristem, and Sunesis
PR Newswire - Tue Mar 11, 8:19AM CDT
Today, Analysts Review released its analysts' notes regarding Hospira Inc. (NYSE: HSP), Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), Revance Therapeutics, Inc. (NASDAQ: RVNC), Pluristem Therapeutics, Inc. (NASDAQ: PSTI), and Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Karyopharm Therapeutics, Inc. (KPTI) Catches Eye: Stock Jumps 13.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 7:44AM CST
Karyopharm Therapeutics, Inc. was a big mover last session, as the company saw its shares surge 14% on the day

Karyopharm Therapeutics Reports 2013 Year-End Financial Results and Provides Update on Clinical Development Plans
GlobeNewswire - Wed Mar 05, 5:30AM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, reported financial results for the year ended December 31, 2013, and also provided an update on its clinical development plans.

Karyopharm Therapeutics Announces Initiation of an Investigator Sponsored Phase 1 Dose Escalation Study of Its Lead Drug Candidate Selinexor (KPT-330) in Singapore
GlobeNewswire - Thu Feb 27, 8:53AM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the initiation of a Phase 1 study of oral Selinexor in Asian patients with advanced or metastatic solid tumors. Selinexor (KPT-330), is a first-in-class, oral Selective Inhibitors of Nuclear Export (SINE) compound that covalently inhibits exportin-1 (XPO1/CRM1), which leads to the accumulation of tumor suppressor proteins in the cell nucleus and the selective induction of apoptosis in cancer cells. This study is designed to determine the recommended Phase 2 dose and assess the safety and preliminary evidence of anti-cancer activity in Asian patients. The study is being conducted by Drs. David Tan and Goh Boon Cher at the National University Cancer Institute, Singapore (NCIS)/National University Hospital (NUH) in Singapore. Dr. Tan is a consultant medical oncologist at the Department of Haematology-Oncology and Assistant Professor at the Yong Loo Lin School of Medicine, National University of Singapore (NUS). Dr. Goh is Head of the Department of Haematology-Oncology and Deputy Director of the Cancer Science Institute of Singapore at the National University of Singapore.

Karyopharm Therapeutics Announces Nine Presentations on its Selective Inhibitors of Nuclear Export (SINE) Compounds and PAK4 Inhibitors at the American Association of Cancer Research (AACR) Meeting
GlobeNewswire - Wed Feb 26, 3:09PM CST
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the presentation of seven posters covering its Selective Inhibitors of Nuclear Export (SINE) compounds and two posters covering its PAK4 inhibitors at the American Association of Cancer Research (AACR) meeting being held April 5-9, 2014 in San Diego, CA. Karyopharm's lead drug candidate, Selinexor (KPT-330), is a first-in-class, oral SINE compound that is undergoing Phase 1 studies in patients with advanced hematologic malignancies, solid tumors, and sarcomas. Karyopharm's allosteric PAK4 inhibitors are in preclinical development.

BioCryst Pharmaceuticals (BCRX) Jumps: Stock Rises 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 8:39AM CST
BioCryst Pharmaceuticals, Inc. was a big mover last session, as its shares rose almost 11% on the day.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

1095 Days Finds the Army's Long, Ordinary War Life

Updated Category News Views 125

A cracked barracks window can explain more than a polished battlefield legend. Dean R. Cherry's 1095 Days: Three Years in the Green Machine, newly released by Palmetto Publishing, puts its weight on the parts of Army life that war stories often shove into the background: cold, waiting, paperwork, arbitrary rules, lousy living conditions, and the private mental math of...

Continue Reading
Evotec’s Second IND Adds Proof to Its Glue Platform

Updated Category News Views 73

Two IND acceptances from one long-running alliance is not nothing, especially in a drug-discovery business where plenty of polished platform talk never makes it to the clinic. Evotec has cleared that modest but meaningful bar again with Bristol Myers Squibb: a second molecular-glue candidate has received FDA acceptance for an Investigational New Drug application. The...

Continue Reading
Dimora's MegaSorb Review Sharpens Wound Care Choices

Updated Category News Views 105

Wound care is one of those corners of healthcare where flashy language runs into real-life consequences fast. Dimora Medical’s newly announced collaboration with podiatric physician Dr. Ebonie Vincent-Sleet brings a professional voice to its MegaSorb silicone foam dressing line, specifically a 4×4-inch product reviewed for its intended place in care. That is useful...

Continue Reading
Common Tiger Bets $499 on Better Outdoor Seating Design

Updated Category News Views 59

A chair that refuses to slump into the camping aisle is Common Tiger's whole argument, and frankly it is a smarter argument than another flimsy fold-up contraption pretending comfort is optional. The Los Angeles, female-founded and women-owned brand is launching with one product, The Daymaker, after four years of development. That is a long runway for a debut chair, which...

Continue Reading
Somerville’s New Immersive Bet Has Room to Grow Locally

Updated Category News Views 167

A passcard, a hidden door, and 12,000 square feet of mischief have landed at Somernova. Edge of Elsewhere, the new flagship attraction from Boston-area creative studio Midnight Mansion, is open in Somerville’s Union Square as of November 18, 2026. It is part interactive art installation, part puzzle game, part physical story world. That sounds delightfully odd, which is...

Continue Reading
Neusoft's OneCoreGo Win Puts Auto Software in Focus

Updated Category News Views 60

A Dashboard Award Is Not Just About Pretty Pixels Crystal-like graphics and augmented-reality pathways may sound like the sort of thing a marketing department dreams up after too much coffee, but the more interesting bit in Neusoft's latest news is the machinery underneath. OneCoreGo 7.0 has received the Red Dot Design Award after taking a German iF Design Award earlier...

Continue Reading
MegaRobo's Nearly $200 Million Bet on Learning Labs

Updated Category News Views 98

A lab robot that merely follows instructions is old news; a system that learns from the mess it makes is the expensive part. MegaRobo has raised nearly US$200 million to push toward that harder prize: infrastructure that links AI reasoning to actual experiments, instruments, automation and the results that come back. For investors watching AI for Science, this is more...

Continue Reading
Innoviz's 1-for-20 Split Is a Listing Lifeline Test

Updated Category News Views 112

A twenty-share pile of INVZ is about to become one share, and nobody should confuse that paperwork with a turnaround. Innoviz plans to enact a 1-for-20 reverse split at 11:59 p.m. Eastern on Friday, December 4, with split-adjusted trading expected when Nasdaq opens on December 7. This is a blunt instrument aimed at one immediate problem: getting the quoted share price...

Continue Reading
Dar Global’s $700M Qatar Bet Leans on Trump Branding

Updated Category News Views 7

Luxury property launches rarely arrive quietly, and this one came wrapped in Palm Beach ceremony, championship golf and a very loud brand name. Dar Global has formally introduced Trump International Simaisma, Qatar, a QAR 2.5 billion development—about $700 million—alongside The Trump Organization. That is a meaningful chunk of real estate ambition, not a little side...

Continue Reading
EmTech AI 2027 Puts AI Ambitions Through Reality Test

Updated Category News Views 5

A three-day gathering cannot settle AI's biggest arguments, but MIT Technology Review has picked the right fight for EmTech AI 2027: make the industry face a Reality Test. The conference runs May 11–13, 2027, at MIT's campus and online, and that theme lands because the AI conversation has spent plenty of time admiring the engine while skipping the ugly maintenance bill....

Continue Reading

Top 5 Most Recently Viewed Articles

City Office REIT's 2024 Q3 Performance and Strategic Outlook

Updated Category News Views 266

City Office REIT's Third Quarter 2024 Financial Results Overview City Office REIT, Inc. (NYSE: CIO) has recently released its financial results for the third quarter of 2024. In this quarter's report, the company highlighted a substantial progression in its office real estate fundamentals, showcasing resilience and strategic maneuvers in a competitive market. Key...

Continue Reading
Latest Transactions of Ringkjøbing Landbobank A/S Shares

Updated Category News Views 146

Overview of Share Transactions In the realm of financial regulations, the duty of disclosure plays a crucial role. When it comes to transactions involving shares, companies must adhere to specific guidelines to maintain transparency. Recently, Ringkjøbing Landbobank A/S has reported its share transactions, which is particularly important for stakeholders, regulatory...

Continue Reading
Unlocking Success: The Power of Trust in Business Practices

Updated Category News Views 280

Trust as the Foundation of Business Success Recent insights have emerged showing that trust not only fosters a positive workplace culture but also serves as a significant catalyst for long-term financial prosperity. According to research from Great Place To Work®, companies that prioritize trust within their employee relationships consistently outperform their...

Continue Reading
Investing in Texas Instruments: A 15-Year Journey of Growth

Updated Category News Views 126

The Impressive Growth of Texas Instruments Texas Instruments (NASDAQ: TXN), a leader in semiconductor technology, has demonstrated remarkable performance over the last 15 years. With an annualized return of 15.69%, it has surpassed market averages by 3.27%. This kind of consistent growth illustrates why many investors find TXN appealing. Your $1000 Investment in TXN If an...

Continue Reading
Sarah Schmelzel Joins SERVPRO as New Brand Ambassador

Updated Category News Views 414

Sarah Schmelzel Becomes a SERVPRO Brand Ambassador Gallatin, Tennessee – SERVPRO, a well-regarded leader in cleanup, restoration, and construction, proudly announces the partnership with LPGA golfer Sarah Schmelzel as a brand ambassador for the upcoming season. This collaboration underscores SERVPRO’s deep-rooted involvement with top-tier sports organizations,...

Continue Reading